Hints and tips:
...John Pearson, chief executive of the German group’s Express division, which is involved in distributing the jab produced by BioNTech and Pfizer, told the Financial Times it can serve 85 per cent of the destinations...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...Brunswick Group hired former Pfizer China government affairs vice-president Xi Qing as a partner in Asia....
...People close to Pfizer say the discussions were tentative but they were sufficiently serious to warrant consideration by Valeant’s board....
...The man who took this most to heart was Michael Pearson, a former McKinsey partner, who as chief executive turned Valeant into an acquisition vehicle that systematically stripped research from its conquests...
...Pfizer (Biotech & Pharma) 36. JPMorgan Chase (Finance) 37. Diageo (Consumer Goods) 38. General Electric (Industrial conglomerate) 39. Chevron (Oil & Gas) 40. Deutsche Bank (Finance) 41....
...The transaction comes after Pfizer announced a $17bn deal to buy Hospira earlier this month and after Shire acquired NPS for $5.2bn in January, suggesting that consolidation in the pharmaceutical industry...
...Pfizer could also consider buying Actavis if the company stops expanding, healthcare bankers said. Pfizer declined to comment....
...No,” Mr Pearson told the FT last month. Allergan’s defence strategy initially focused on discrediting Valeant’s business model....
...Now that Abbvie’s £35bn bid for Shire has collapsed and the chances of Pfizer making a fresh £69bn bid for AstraZeneca have greatly diminished, it is also the sector’s biggest potential deal of the year....
...All this has implications for Pfizer, the biggest US drugmaker, which has been linked with Actavis as a potential alternative to AstraZeneca, which rebuffed its £69bn offer in May....
...economic benefits based, directly or indirectly, on the value or price of, any capital stock of, or other securities or ownership interests in, the Company (the items in clauses (i), (ii), (iii), (iv) and (v)...
...“We believe our stock is trading at artificially low levels,” Mr Pearson said in the letter....
...Michael Pearson, Valeant’s chief executive, likened his approach to the tech industry, where many of best innovations come from small Silicon Valley start-ups....
...Michael Pearson, Valeant’s chief executive, was a “very disciplined” bidder and would have to think about his own shareholders when deciding whether to make a higher offer, they said....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...That produced dubious results but, undaunted, Pfizer has suggested a $100bn merger to AstraZeneca of the UK....
...asked Mike Pearson, Valeant’s chief executive, in a meeting with analysts last week....
...The same goes for Pfizer’s approach to AstraZeneca, revealed a few days after the swoop on Allergan....
...Related reading: China’s nappy war: Mamy Poko v Pampers & Huggies, beyondbrics Nappies, growth and the bottom line, FT Kimberly-Clark takes aim at Russian nappy market, beyondbrics...
...Actavis is seeking to acquire Warner Chilcott of Ireland, and Pfizer last week said it would fully divest its remaining 80 per cent stake of Zoetis, its animal health division, by the start of next year....
International Edition